Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics is projecting annual sales of its primary product, Korlym, to grow between 19% and 26% year-over-year, indicating strong underlying demand and the company’s ability to navigate recent commercial challenges. The positive clinical trial results for relacorilant in combination with nab-paclitaxel demonstrate its potential to significantly benefit patients with advanced ovarian cancer, which could lead to expanded indications and market opportunities. Additionally, the anticipated favorable regulatory outcomes for relacorilant in treating hypercortisolism further enhance the company's growth prospects, positioning it for substantial market expansion in the coming years.

Bears say

Corcept Therapeutics Inc has revised its financial outlook significantly, lowering its 12-month price target from $145 to $90 per diluted share due to the recent Complete Response Letter (CRL) and anticipated delays in launching relacorilant for Cushing's Syndrome treatment. The company's stock experienced a notable decline, closing at approximately $35, reflecting a loss of -50.4%, which highlights market concerns regarding its revenue projections and commercial distribution changes. Given these developments and the uncertainty surrounding future earnings and sales growth, there are fundamental reasons for a negative outlook on the stock despite management's previous successes in drug launches.

Corcept Therapeutics (CORT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 5 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Jan 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $111, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $111, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.